Sofosbuvir shows promise for chronic hepatitis C infection

April 23, 2013
Sofosbuvir shows promise for chronic hepatitis C infection
Sofosbuvir seems to be a promising treatment option for patients with chronic hepatitis C virus infection, according to two studies published online April 23 in the New England Journal of Medicine to coincide with presentation at The International Liver Congress, the annual meeting of the European Association for the Study of the Liver, held from April 24 to 28 in Amsterdam.

(HealthDay)—Sofosbuvir seems to be a promising treatment option for patients with chronic hepatitis C virus (HCV) infection, according to two studies published online April 23 in the New England Journal of Medicine to coincide with presentation at The International Liver Congress, the annual meeting of the European Association for the Study of the Liver, held from April 24 to 28 in Amsterdam.

Ira M. Jacobson, M.D., from Weill Cornell Medical College in New York, and colleagues conducted two randomized phase 3 studies involving patients with chronic HCV genotype 2 or 3. The researchers found that the rate of sustained was 78 percent with sofosbuvir and ribavirin versus 0 percent with placebo in patients for whom peginterferon treatment was not an option. For previously treated non-responders, the rate of response with sofosbuvir and ribavirin was 50 percent at 12 weeks and 73 percent at 16 weeks.

Eric Lawitz, M.D., from the Texas Liver Institute in San Antonio, and colleagues conducted two phase 3 studies in previously untreated patients with HCV. The researchers found that in a single-group study the sustained virologic response was 90 percent with a 12-week regimen of sofosbuvir plus peginterferon alfa-2a and ribavirin. In the non-inferiority trial, the sustained virologic response was 67 percent for patients treated with 12 weeks of sofosbuvir plus ribavirin and 67 percent for those treated with 24 weeks of -2a plus ribavirin.

"The data from the sofosbuvir trials suggest that a radical change in clinical practice is imminent," write the authors of an accompanying editorial.

Several authors from the Jacobson study disclosed financial ties to pharmaceutical companies, including Gilead Sciences, which manufactures sofosbuvir and funded both studies.

More information: Full Text - Jacobson
Full Text - Lawitz
Editorial
More Information

Related Stories

Coffee drinking improves hepatitis C treatment response

June 7, 2011

Advanced hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association ...

Interferon-free therapies for hep C virus look promising

January 3, 2013

(HealthDay)—For untreated patients with hepatitis C virus (HCV), treatment with an oral nucleotide inhibitor of HCV polymerase, sofosbuvir, plus ribavirin seems effective for genotypes 1, 2, and 3; and the HCV NS3 protease ...

Recommended for you

Experimental MERS vaccine shows promise in animal studies

July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.